PMID- 28155628
OWN - NLM
STAT- MEDLINE
DCOM- 20180529
LR  - 20220318
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 15
IP  - 6
DP  - 2017
TI  - Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and 
      Challenges.
PG  - 557-565
LID - 10.2174/1570161115666170202162345 [doi]
AB  - BACKGROUND: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that 
      degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs 
      are major regulators of ECM degradation as well as structural and functional 
      integrity in the glomerulus. In altered matrix composition diseases, glomerular 
      damage is due to increased degradation of kidney and vessel basement membranes 
      (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade 
      collagen type-IV (coll-IV), which represents the key collagenous component of ECM 
      and constitutes the architectural structure of vessels and glomerular BM. There 
      is growing evidence implicating MMPs in atherosclerosis as well as in 
      cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific 
      endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and 
      diabetic nephropathy (DN). CONCLUSION: The present review discusses the role of 
      MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model 
      of the link between progressive glomerulosclerosis and MMP expression.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Dimas, Grigorios G
AU  - Dimas GG
AD  - 13 Dimokratias Str. Panorama, PC 55236, Thessaloniki. Greece.
FAU - Didangelos, Triantafyllos P
AU  - Didangelos TP
AD  - First Propaedeutic Medical Department of Internal Medicine, AHEPA University 
      Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki. 
      Greece.
FAU - Grekas, Dimitrios M
AU  - Grekas DM
AD  - First Propaedeutic Medical Department of Internal Medicine, AHEPA University 
      Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki. 
      Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - EC 3.4.24.- (Gelatinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Animals
MH  - Atherosclerosis/*metabolism
MH  - Diabetic Nephropathies/*metabolism
MH  - Gelatinases/*metabolism
MH  - Humans
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
OTO - NOTNLM
OT  - Matrix metalloproteinases
OT  - atherosclerosis
OT  - diabetic nephropathy
OT  - gelatinases
OT  - glomerulosclerosis
OT  - proteinuria
EDAT- 2017/02/06 06:00
MHDA- 2018/05/31 06:00
CRDT- 2017/02/04 06:00
PHST- 2016/05/21 00:00 [received]
PHST- 2016/12/13 00:00 [revised]
PHST- 2016/12/30 00:00 [accepted]
PHST- 2017/02/06 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
PHST- 2017/02/04 06:00 [entrez]
AID - CVP-EPUB-81457 [pii]
AID - 10.2174/1570161115666170202162345 [doi]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2017;15(6):557-565. doi: 10.2174/1570161115666170202162345.